V. Alonso-Orduna

TL;DR: Maintenance of VEGF inhibition with bevacizumab plus standard second-line chemotherapy beyond disease progression has clinical benefits in patients with metastatic colorectal cancer.

TL;DR: This study did not show survival benefits after treatment personalization based on polymorphisms in mCRC, but the improved ORR and R0 resection rate and fewer disabling toxicities suggest that tailoring therapy by TYMS-3'UTR and ERCC1-118 polymorphisms warrants further investigation in patients withmCRC.

TL;DR: The biomarker findings from this study suggest that patients with both WT and MT KRAS tumours are likely to benefit from bevacizumab treatment, and this is the first randomized study evaluating the benefit of continuingBevacIZumab in combination with standard chemotherapy as second-line treatment for patients with mCRC who progressed after receiving a standard bevacsumab-containing regimen in the first-line setting.

TL;DR: This post-hoc subgroup analysis suggests that continuing BEV + 2L oxaliplatin or irinotecan-based CT (following crossover) leads to prolonged OS and PFS, regardless of the type of oxali Platin or Iris CT used 1L.

TL;DR: The findings demonstrate that bevacizumab + chemotherapy (crossed over from the first-line regimen) continued beyond progression significantly prolongs OS and PFS in the second-line mCRC setting.